Organoid Based Response Prediction in Esophageal Cancer

Launched by UNIVERSITY MEDICAL CENTER GRONINGEN · Sep 12, 2017

Keywords

ClinConnect Summary

This clinical trial is studying a new way to predict how well patients with esophageal cancer will respond to treatment called neoadjuvant chemoradiotherapy (nCRT). The goal is to create small lab-grown models of the patients' tumors, known as organoids, which can help doctors see how the cancer will react to different therapies. By understanding the tumor's response before surgery, doctors can tailor treatments to individual patients, potentially allowing for treatments that preserve the esophagus or switch to different therapies if the cancer does not respond as expected.

To participate in this trial, patients must be at least 18 years old and have a confirmed diagnosis of esophageal cancer that can be treated with surgery. Those eligible will undergo a procedure called endoscopic ultrasound (EUS), where doctors will collect some extra tissue samples to create the organoids. While these additional biopsies have similar risks to standard procedures, participants should know that they won’t receive direct benefits from being in the study. However, the findings could lead to better treatment options for future patients with esophageal cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically proven adeno- or squamous cell carcinoma of the esophagus
• • Age ≥ 18 years
• • Candidates for curative treatment; clinical stage T1N+/T2-4aN0-3M0
• • Scheduled for endoscopic ultrasound (EUS) procedure for staging and/or treatment purposes
• • Written informed consent
• Exclusion Criteria:
• • Patients who are medically unfit for a curative treatment
• • Signs of distant metastases (M1)
• • Patients who are mentally disabled or incapable to give informed consent